Heron Therapeutics (HRTX) Momentum on Top-Line Study Results
Post# of 88
Posted On: 05/29/2015 6:44:08 AM
Shares of Heron Therapeutics, Inc. (HRTX) soared to reach a record high in extended-hours trading Thursday after the company reported positive, top-line results from its recently completed Phase 3 MAGIC study.
According to HRTX, its 5-HT3 receptor antagonist product candidate SUSTOL (granisetron injection, extended release), as part of a three-drug regimen, demonstrated superiority to the currently recommended standard-of-care, three-drug regimen (which uses ondansetron as 5-HT3 receptor antagonist) for delayed nausea and vomiting after administration of highly emetogenic chemotherapy agents.
HRTX also said that SUSTOL-based regimen was associated with significantly reduced nausea and improved patient satisfaction
HRTX's immediate focus is now the resubmission of its New Drug Application (NDA) for SUSTOL to the U.S. Food and Drug Administration (FDA), which the company expects in mid-2015. In addition, HRTX is planning for the commercial launch of SUSTOL, pending FDA approval.
HRTX is a biotechnology company using its proprietary technology and innovative efforts to develop products to address unmet medical needs.
More about Heron Therapeutics, Inc. (HRTX) at www.herontx.com
**
The price of the stock of Rosetta Stone, Inc. (RST) climbed significantly in after-hours trading Thursday following a story from Mergermarket indicating that a group of private equity investors have offered to purchase the company for between $9-$10 per share.
RST recently reported revenues of $58.4 million for the first quarter 2015.
RST is dedicated to changing the way the world learns. Its innovative technology-driven language, reading and brain-fitness solutions are used by thousands of schools, businesses, government organizations and millions of individuals around the world.
More about Rosetta Stone, Inc. (RST) at www.rosettastone.com.
**
Crown Equity Holdings Inc. (CRWE) has updated its business plan ( http://crownequityholdings.com/extras/Business_Plan.pdf )
The company is currently developing its CRWE PR Network, which disseminates community, state, national and global news & information and is also the portal in promoting the company’s services, such as its business directory, business-to-business global trading, real estate, press release and video distribution, discounted vouchers and advertising platforms.
CRWE‘s growing network of community targeted sites is expected to be a one-stop shop for the various needs of consumers.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
According to HRTX, its 5-HT3 receptor antagonist product candidate SUSTOL (granisetron injection, extended release), as part of a three-drug regimen, demonstrated superiority to the currently recommended standard-of-care, three-drug regimen (which uses ondansetron as 5-HT3 receptor antagonist) for delayed nausea and vomiting after administration of highly emetogenic chemotherapy agents.
HRTX also said that SUSTOL-based regimen was associated with significantly reduced nausea and improved patient satisfaction
HRTX's immediate focus is now the resubmission of its New Drug Application (NDA) for SUSTOL to the U.S. Food and Drug Administration (FDA), which the company expects in mid-2015. In addition, HRTX is planning for the commercial launch of SUSTOL, pending FDA approval.
HRTX is a biotechnology company using its proprietary technology and innovative efforts to develop products to address unmet medical needs.
More about Heron Therapeutics, Inc. (HRTX) at www.herontx.com
**
The price of the stock of Rosetta Stone, Inc. (RST) climbed significantly in after-hours trading Thursday following a story from Mergermarket indicating that a group of private equity investors have offered to purchase the company for between $9-$10 per share.
RST recently reported revenues of $58.4 million for the first quarter 2015.
RST is dedicated to changing the way the world learns. Its innovative technology-driven language, reading and brain-fitness solutions are used by thousands of schools, businesses, government organizations and millions of individuals around the world.
More about Rosetta Stone, Inc. (RST) at www.rosettastone.com.
**
Crown Equity Holdings Inc. (CRWE) has updated its business plan ( http://crownequityholdings.com/extras/Business_Plan.pdf )
The company is currently developing its CRWE PR Network, which disseminates community, state, national and global news & information and is also the portal in promoting the company’s services, such as its business directory, business-to-business global trading, real estate, press release and video distribution, discounted vouchers and advertising platforms.
CRWE‘s growing network of community targeted sites is expected to be a one-stop shop for the various needs of consumers.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
(0)
(0)Heron Therapeutics, Inc. (HRTX) Stock Research Links
Scroll down for more posts ▼